AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2.
Marah G ChibwanaThandeka Moyo-GweteGaurav KwatraJonathan MandoloTandile HermanausThopisang MotlouNonkululeko MzindleFrances AyresMphatso ChapondaGodwin TemboPercy MwenechanyaNdaona MitoleChisomo JassiRaphael Kamng'onaLouise AfranDavid MzinzaHenry C MwandumbaStephen B GordonKhuzwayo JereShabir MadhiPenny L MooreRobert S HeydermanKondwani C JamboPublished in: BMC medicine (2022)
These findings show that the AstraZeneca COVID-19 vaccine is an effective booster for waning cross-variant antibody immunity after initial priming with SARS-CoV-2 infection. The potency of hybrid immunity and its potential to maximise the benefits of COVID-19 vaccines needs to be taken into consideration when formulating vaccination policies in sub-Saharan Africa, where there is still limited access to vaccine doses.